Deutsche Bank AG bought a new position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 353,552 shares of the biotechnology company's stock, valued at approximately $5,172,000. Deutsche Bank AG owned 2.64% of Anika Therapeutics as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of the business. AQR Capital Management LLC acquired a new position in shares of Anika Therapeutics in the 1st quarter valued at $181,000. Cetera Investment Advisers boosted its position in shares of Anika Therapeutics by 93.1% in the 2nd quarter. Cetera Investment Advisers now owns 19,509 shares of the biotechnology company's stock worth $206,000 after purchasing an additional 9,407 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Anika Therapeutics by 32.8% during the second quarter. American Century Companies Inc. now owns 44,161 shares of the biotechnology company's stock worth $467,000 after purchasing an additional 10,909 shares during the period. Marshall Wace LLP acquired a new stake in shares of Anika Therapeutics during the second quarter worth $241,000. Finally, Jane Street Group LLC increased its holdings in Anika Therapeutics by 31.6% in the second quarter. Jane Street Group LLC now owns 22,871 shares of the biotechnology company's stock valued at $242,000 after purchasing an additional 5,488 shares during the last quarter. Institutional investors and hedge funds own 91.53% of the company's stock.
Wall Street Analysts Forecast Growth
ANIK has been the topic of several analyst reports. Barrington Research set a $21.00 target price on Anika Therapeutics in a research note on Thursday, July 30th. B. Riley Financial boosted their target price on Anika Therapeutics from $18.00 to $21.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Zacks Research raised Anika Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, August 5th. Wall Street Zen upgraded shares of Anika Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 1st. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Anika Therapeutics in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Anika Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $21.00.
Read Our Latest Research Report on ANIK
Anika Therapeutics Stock Down 2.0%
NASDAQ ANIK opened at $21.34 on Tuesday. Anika Therapeutics Inc. has a 12-month low of $8.37 and a 12-month high of $22.88. The company has a market capitalization of $285.59 million, a PE ratio of -79.03, a price-to-earnings-growth ratio of 15.56 and a beta of 0.20. The firm's 50 day moving average is $17.19 and its 200-day moving average is $15.09.
Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.03 by $0.39. The business had revenue of $32.61 million during the quarter, compared to analysts' expectations of $29.21 million. Anika Therapeutics had a negative net margin of 3.14% and a positive return on equity of 0.20%. As a group, sell-side analysts expect that Anika Therapeutics Inc. will post 0.14 EPS for the current year.
About Anika Therapeutics
(
Free Report)
Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika's proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.
The company's core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Anika Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anika Therapeutics wasn't on the list.
While Anika Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
